Open AccessReal‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
Author(s) -
Leleu Xavier,
Katodritou Eirini,
Kuehr Thomas,
Terpos Evangelos,
Caers Jo,
Zambello Renato,
Brescianini Alessandra,
Liang Tony,
Wetten Sally,
Badelita Sori.
Publication year - 2023
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.595
Subject(s) - carfilzomib , lenalidomide , medicine , refractory (planetary science) , discontinuation , dexamethasone , daratumumab , oncology , multiple myeloma , physics , astrobiology
Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients ( n = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti‐CD38 antibody‐refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide‐refractory and not lenalidomide‐refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m 2 ) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real‐world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti‐CD38 antibodies.